Literature DB >> 23596311

HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin.

Natascha Wuillemin1, Jacqueline Adam, Stefano Fontana, Stephan Krähenbühl, Werner J Pichler, Daniel Yerly.   

Abstract

Drug-induced liver injury (DILI) is a main cause of drug withdrawal. A particularly interesting example is flucloxacillin (FLUX)-DILI, which is associated with the HLA-B*57:01 allele. At present, the mechanism of FLUX-DILI is not understood, but the HLA association suggests a role for activated T cells in the pathomechanism of liver damage. To understand the interaction among FLUX, HLA molecules, and T cells, we generated FLUX-reacting T cells from FLUX-naive HLA-B*57:01(+) and HLA-B*57:01(-) healthy donors and investigated the mechanism of T cell stimulation. We found that FLUX stimulates CD8(+) T cells in two distinct manners. On one hand, FLUX was stably presented on various HLA molecules, resistant to extensive washing and dependent on proteasomal processing, suggesting a hapten mechanism. On the other hand, in HLA-B*57:01(+) individuals, we observed a pharmacological interaction with immune receptors (p-i)-based T cell reactivity. FLUX was presented in a labile manner that was further characterized by independence of proteasomal processing and immediate T cell clone activation upon stimulation with FLUX in solution. This p-i-based T cell stimulation was restricted to the HLA-B*57:01 allele. We conclude that the presence of HLA-B*57:01 drives CD8(+) T cell responses to the penicillin-derivative FLUX toward nonhapten mechanism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23596311     DOI: 10.4049/jimmunol.1202949

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Authors:  Lisa M Wheatley; Marshall Plaut; Julie M Schwaninger; Aleena Banerji; Mariana Castells; Fred D Finkelman; Gerald J Gleich; Emma Guttman-Yassky; Simon A K Mallal; Dean J Naisbitt; David A Ostrov; Elizabeth J Phillips; Werner J Pichler; Thomas A E Platts-Mills; Jean-Claude Roujeau; Lawrence B Schwartz; Lauren A Trepanier
Journal:  J Allergy Clin Immunol       Date:  2015-08       Impact factor: 10.793

Review 2.  Pharmacogenomics of antimicrobial agents.

Authors:  Ar Kar Aung; David W Haas; Todd Hulgan; Elizabeth J Phillips
Journal:  Pharmacogenomics       Date:  2014       Impact factor: 2.533

Review 3.  Multiple Drug Hypersensitivity.

Authors:  Werner J Pichler; Yuttana Srinoulprasert; James Yun; Oliver Hausmann
Journal:  Int Arch Allergy Immunol       Date:  2017-03-18       Impact factor: 2.749

Review 4.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

Review 5.  Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.

Authors:  Robert J Fontana
Journal:  Gastroenterology       Date:  2013-12-31       Impact factor: 22.682

6.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

Review 7.  The role of HLA genes in pharmacogenomics: unravelling HLA associated adverse drug reactions.

Authors:  Patricia T Illing; Anthony W Purcell; James McCluskey
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 3.330

8.  Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses.

Authors:  Jacqueline Adam; Natascha Wuillemin; Stephan Watkins; Heidi Jamin; Klara K Eriksson; Peter Villiger; Stefano Fontana; Werner J Pichler; Daniel Yerly
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

Review 9.  Update on Advances in Research on Idiosyncratic Drug-Induced Liver Injury.

Authors:  Seung Hyun Kim; Dean J Naisbitt
Journal:  Allergy Asthma Immunol Res       Date:  2015-07-03       Impact factor: 5.764

10.  Negative regulation by PD-L1 during drug-specific priming of IL-22-secreting T cells and the influence of PD-1 on effector T cell function.

Authors:  Andrew Gibson; Monday Ogese; Andrew Sullivan; Eryi Wang; Katy Saide; Paul Whitaker; Daniel Peckham; Lee Faulkner; B Kevin Park; Dean J Naisbitt
Journal:  J Immunol       Date:  2014-02-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.